Hanmi Hits Jackpot Again, This Time With Janssen
This article was originally published in Scrip
Executive Summary
Hanmi Pharmaceutical Co. Ltd. has inked a licensing out agreement with Janssen Pharmaceutical Co. for the development and commercialization of its diabetes and obesity therapy HM12525A, a long-acting GLP/GCG analog.